Literature DB >> 20079874

Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus.

J Kortekaas1, A Dekker, S M de Boer, K Weerdmeester, R P M Vloet, A A C de Wit, B P H Peeters, R J M Moormann.   

Abstract

In the past decade, the use of Newcastle disease virus (NDV) as a vaccine vector for the prevention of economically important livestock diseases as well as for human diseases has been extensively explored. In this study, we have constructed a recombinant NDV vaccine virus, named NDFL-Gn, that produces the Rift Valley fever virus (RVFV) Gn glycoprotein. Calves were immunized via either the intranasal route or the intramuscular route. Delivery via the intranasal route elicited no detectable antibody responses, whereas delivery via the intramuscular route elicited antibodies against both NDV and the Gn protein. The RVFV-neutralizing activity of the antisera from intramuscularly vaccinated calves was demonstrated, suggesting that NDV is a promising vaccine vector for the prevention of RVF in calves. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20079874     DOI: 10.1016/j.vaccine.2010.01.001

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats.

Authors:  Jinying Ge; Xijun Wang; Lihong Tao; Zhiyuan Wen; Na Feng; Songtao Yang; Xianzhu Xia; Chinglai Yang; Hualan Chen; Zhigao Bu
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  Rift valley fever: recent insights into pathogenesis and prevention.

Authors:  Hani Boshra; Gema Lorenzo; Núria Busquets; Alejandro Brun
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

3.  A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep.

Authors:  Bonto Faburay; Maxim Lebedev; D Scott McVey; William Wilson; Igor Morozov; Alan Young; Juergen A Richt
Journal:  Vector Borne Zoonotic Dis       Date:  2014-10       Impact factor: 2.133

4.  Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters.

Authors:  Rik L de Swart; Olav S de Leeuw; Nadia Oreshkova; Nora M Gerhards; Irina C Albulescu; Sandra Vreman; José L Gonzales; Riks Maas; Frank J M van Kuppeveld; Peter Soema; Berend-Jan Bosch; Ben P H Peeters
Journal:  Vaccine       Date:  2022-07-06       Impact factor: 4.169

5.  Acid-activated structural reorganization of the Rift Valley fever virus Gc fusion protein.

Authors:  S M de Boer; J Kortekaas; L Spel; P J M Rottier; R J M Moormann; B J Bosch
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

6.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

7.  Rescue of a recombinant Newcastle disease virus strain R2B expressing green fluorescent protein.

Authors:  Madhan Mohan Chellappa; Sohini Dey; Satish Gaikwad; Dinesh C Pathak; Vikram N Vakharia
Journal:  Virus Genes       Date:  2017-02-09       Impact factor: 2.332

8.  Functional analysis of Rift Valley fever virus NSs encoding a partial truncation.

Authors:  Jennifer A Head; Birte Kalveram; Tetsuro Ikegami
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

9.  Rift Valley Fever Vaccine Development, Progress and Constraints.

Authors:  Jeroen Kortekaas; James Zingeser; Peter de Leeuw; Stephane de La Rocque; Hermann Unger; Rob J M Moormann
Journal:  Emerg Infect Dis       Date:  2011-09       Impact factor: 6.883

Review 10.  Novel approaches to develop Rift Valley fever vaccines.

Authors:  Sabarish V Indran; Tetsuro Ikegami
Journal:  Front Cell Infect Microbiol       Date:  2012-10-26       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.